Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Long-Term Investments (2021 - 2025)

C4 Therapeutics (CCCC) has 5 years of Long-Term Investments data on record, last reported at $48.6 million in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 117.2% year-over-year to $48.6 million; the TTM value through Dec 2025 reached $48.6 million, up 117.2%, while the annual FY2025 figure was $48.6 million, 117.2% up from the prior year.
  • Long-Term Investments reached $48.6 million in Q4 2025 per CCCC's latest filing, up from $7.9 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $142.2 million in Q4 2021 and bottomed at $7.9 million in Q3 2025.
  • Average Long-Term Investments over 5 years is $47.0 million, with a median of $32.6 million recorded in 2021.
  • Peak YoY movement for Long-Term Investments: soared 301.53% in 2022, then plummeted 78.44% in 2023.
  • A 5-year view of Long-Term Investments shows it stood at $142.2 million in 2021, then crashed by 57.13% to $61.0 million in 2022, then crashed by 54.06% to $28.0 million in 2023, then dropped by 20.17% to $22.4 million in 2024, then soared by 117.2% to $48.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $48.6 million in Q4 2025, $7.9 million in Q3 2025, and $8.4 million in Q2 2025.